March 13, 2026 - PRESSADVANTAGE - Infintech Designs published a detailed blog addressing the strategy, methodology, and ...
TRAILBLAZER-2, a Phase 3 study, has enrolled 1,600 participants. Prescreening with plasma p-tau-181 helped select people with both amyloid and tau pathology. A secondary prevention trial, ...
Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results